Talacotuzumab
As of the edition of 20 October 2026, Talacotuzumab is an antibody: went quiet in 2021; acts on IL3RA.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2021
- Kind
- Antibody
- Registered trials
- 5, 2 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 companies on route A because of this drug.
Companies on route A for this drug
In the product3 companies are on route A because of Talacotuzumab.
See the 3 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IL3RA | Interleukin-3 receptor subunit alpha | P26951 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 1 | 0 | 1 |
| Phase 2 | 2 | 1 | 0 | 1 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Sanofi | Lead sponsor of trials | 2012 to now |
| Johnson & Johnson | Lead sponsor of trials | 2015 to now |
| Gwt-Tud | Lead sponsor of trials | 2016 to now |